PCN44 Cost-Effectiveness of Durvalumab Following Chemoradiotherapy in Unresectable Stage III NSCLC Patients in the US: An Update Based on 4-Year Survival Data
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.136
https://www.valueinhealthjournal.com/article/S1098-3015(21)00353-3/fulltext
Title :
PCN44 Cost-Effectiveness of Durvalumab Following Chemoradiotherapy in Unresectable Stage III NSCLC Patients in the US: An Update Based on 4-Year Survival Data
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00353-3&doi=10.1016/j.jval.2021.04.136
First page :
Section Title :
Open access? :
No
Section Order :
10712